Telix Pharmaceuticals: Q3 revenue of US$245M, up 19% year on year
FROM THE WIRE · SEEKINGALPHA.COM
* Telix Pharmaceuticals press release [https://seekingalpha.com/pr/20693628-telix-reports-third-quarter-2026-financial-performance] (TLX [https://seekingalpha.com/symbol/TLX]): Q3 revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralResults in line with expectations and reaffirmed 2026 guidance make this ordinary flow for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 revenue was US$245 million, up 19% over the prior year quarter.
- 02The company reaffirmed FY 2026 revenue and other income expected above US$1 billion.
- 03FY 2026 R&D expenditure guidance was revised to US$240 million to US$260 million.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets